Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: Pooled analysis of extension phases of two Phase III trials

Neurogastroenterology and Motility

Volumn 26, Issue 12, 2014, Pages 1792-1801

  Blagden, M ^a   Hafer, J ^b   Duerr, H ^c   Hopp, M ^c   Bosse, B ^c  

^a Avondale Surgery   (United Kingdom)

^b Praxis für Schmerztherapie   (Germany)

^c MUNDIPHARMA GMBH   (Germany)

Author keywords

Chronic pain; Constipation; Naloxone; Opioid; Oxycodone

Indexed keywords

ANALGESIC AGENT; DELAYED RELEASE FORMULATION; DRUG COMBINATION; NALOXONE; OXYCODONE; OXYCODONE NALOXONE COMBINATION;

ADULT; AGED; CHEMICALLY INDUCED; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; THERAPEUTIC USE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; CHRONIC PAIN; CONSTIPATION; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; OXYCODONE; SURVEYS AND QUESTIONNAIRES;

EID: 84911489119     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12463     Document Type: Article

References (34)

1. Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: a prevalence study. Pain 2001; 89: 127-34.
2. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333.
3. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 2010; 11: 1230-9.
4. Ng KF, Tsui SL, Chan WS. Prevalence of common chronic pain in Hong Kong adults. Clin J Pain 2002; 18: 275-81.
5. Reid KJ, Harker J, Bala MM, Truyers C, Kellen E, Bekkering GE, Kleijnen J. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011; 27: 449-62.
6. Strine TW, Hootman JM, Chapman DP, Okoro CA, Balluz L. Health-related quality of life, health risk behaviors, and disability among adults with pain-related activity difficulty. Am J Public Health 2005; 95: 2042-8.
7. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-30.
8. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23(Suppl. 7): vii139-54.
9. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag 2009; 5: 137-44.
10. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009; 10: 35-42.
11. Cook SF, Bell TJ, Sweeney CT, Fehnel SE, Hollis K. Impact on quality of life of constipation-associated GI symptoms related to opioid treatment in chronic pain patients: Pac-qol results from the opioid survey. J Pain 2007; 8: S71 (Abstract 883).
12. Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther 2008; 27: 1224-32.
13. Tack J, Muller-Lissner S, Stanghellini V, Boeckxstaens G, Kamm MA, Simren M, Galmiche JP, Fried M. Diagnosis and treatment of chronic constipation-a European perspective. Neurogastroenterol Motil 2011; 23: 697-710.
14. Holzer P, Ahmedzai SH, Niederle N, Leyendecker P, Hopp M, Bosse B, Spohr I, Reimer K. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 2009; 5: 145-51.
15. De LA, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996; 69: 103-15.
16. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004; 11: 3-9.
17. Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Palaniappan K, Church A et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs 2011; 20: 427-39.
18. Brock C, Olesen SS, Olesen AE, Frokjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012; 72: 1847-65.
19. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De CF et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58-68.
20. Napp Pharmaceuticals Limited. Targinact Summary of Product Characteristics. 2013. Available at: http://www.medicines.org.uk.
21. Reimer K, Hopp M, Zenz M, Maier C, Holzer P, Mikus G, Bosse B, Smith K et al. Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach. Pharmacology 2009; 83: 10-7.
22. Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Bell D. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012; 50: 360-7.
23. Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, Bond S, Kremers W et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009; 10: 531-43.
24. Löwenstein O, Leyendecker P, Lux EA, Blagden M, Simpson KH, Hopp M, Bosse B, Reimer K. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010; 10: 12.
25. Simpson K, Leyendecker P, Hopp M, Muller-Lissner S, Lowenstein O, De AJ, Troy FJ, Bosse B et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008; 24: 3503-12.
26. Sandner-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W, Sevcik P, Hakl M et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010; 64: 763-74.
27. European Parliament and Council of the European Union. Clinical Trials Directive 2001/20/EC. 2001. Available at: http://eurlex.europa.eu/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF.
28. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. International Conference on Harmonisation. Guidelines on good clinical practice. 1997. Available at: http://ich.org/.
29. The World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 2002. Available at: http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
30. Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12: 371-83.
31. Ueberall MA, Muller-Lissner S, Buschmann-Kramm C, Bosse B. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res 2011; 39: 41-50.
32. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13: 293-308.
33. Mundin GE, Smith KJ, Mysicka J, Heun G, Kramer M, Hahn U, Leuner C. Validated in vitro/in vivo correlation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times. Expert Opin Drug Metab Toxicol 2012; 8: 1495-503.
34. Muller-Lissner S. Opioid-induced constipation - mechanisms, relevance and management. Eur Gastroenterol Hepatol Review 2010; 6: 54-7.